Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 1
2017 2
2018 3
2019 6
2020 2
2021 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
Conroy JM, Pabla S, Glenn ST, Seager RJ, Van Roey E, Gao S, Burgher B, Andreas J, Giamo V, Mallon M, Lee YH, DePietro P, Nesline M, Wang Y, Lenzo FL, Klein R, Zhang S. Conroy JM, et al. Among authors: lenzo fl. PLoS One. 2021 Dec 2;16(12):e0260089. doi: 10.1371/journal.pone.0260089. eCollection 2021. PLoS One. 2021. PMID: 34855780 Free PMC article.
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Pabla S, Seager RJ, Van Roey E, Gao S, Hoefer C, Nesline MK, DePietro P, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Schoenborn M, Zhang S, Klein R, Glenn ST, Conroy JM. Pabla S, et al. Among authors: lenzo fl. Biomark Res. 2021 Jul 7;9(1):56. doi: 10.1186/s40364-021-00308-6. Biomark Res. 2021. PMID: 34233760 Free PMC article.
Immune profiling and immunotherapeutic targets in pancreatic cancer.
Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. Lenzo FL, et al. Ann Transl Med. 2021 Jan;9(2):119. doi: 10.21037/atm-20-1076. Ann Transl Med. 2021. PMID: 33569421 Free PMC article.
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Gupta R, Zhu J, Labriola M, McCall S, George DJ, Ghatalia P, Dayyani F, Edwards R, Park MS, Singh R, Jacob R, George S, Xu B, Zibelman M, Kurzrock R, Morrison C. Zhang T, et al. Among authors: lenzo fl. Oncoimmunology. 2020 Jun 10;9(1):1773200. doi: 10.1080/2162402X.2020.1773200. Oncoimmunology. 2020. PMID: 32923131 Free PMC article.
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. Kato S, et al. Among authors: lenzo fl. Oncoimmunology. 2020 Feb 17;9(1):1708065. doi: 10.1080/2162402X.2019.1708065. eCollection 2020. Oncoimmunology. 2020. PMID: 32117584 Free PMC article.
Oncologist uptake of comprehensive genomic profile guided targeted therapy.
Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Puzanov I, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Frederick P, Lele S, Gardner M, Morrison C. Nesline MK, et al. Among authors: lenzo fl. Oncotarget. 2019 Jul 23;10(45):4616-4629. doi: 10.18632/oncotarget.27047. eCollection 2019 Jul 23. Oncotarget. 2019. PMID: 31384390 Free PMC article.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Pabla S, et al. Among authors: lenzo fl. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3. J Immunother Cancer. 2019. PMID: 30709424 Free PMC article.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Conroy JM, et al. Among authors: lenzo fl. J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5. J Immunother Cancer. 2019. PMID: 30678715 Free PMC article.
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C. Dy GK, et al. Among authors: lenzo fl. BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x. BMC Med Inform Decis Mak. 2019. PMID: 30658646 Free PMC article.
17 results